Fonte: Vaccines. Unidades: ICB, FM, EACH, FCF, BIOTECNOLOGIA
Assuntos: IMUNIDADE, CAMUNDONGOS, LIPOSSOMOS, VACINAS VIRAIS, INFECÇÕES POR CORONAVIRUS, COVID-19, ADENOVÍRUS, PROTEÍNAS RECOMBINANTES, GLICOPROTEÍNAS, CAMUNDONGOS, VACINAÇÃO
ABNT
RUSSO, Momtchilo et al. Intranasal liposomal formulation of spike protein adjuvanted with CpG protects and boosts heterologous immunity of hACE2 transgenic mice to SARS-CoV-2 infection. Vaccines, v. No 2023, n. 11, p. 01-17, 2023Tradução . . Disponível em: http://dx.doi.org/10.3390/vaccines11111732. Acesso em: 01 set. 2024.APA
Russo, M., Corrêa, M. C. M., Lins, B. B., Kersten, V., Pernambuco Filho, P. C. de A., Martins, T. R., et al. (2023). Intranasal liposomal formulation of spike protein adjuvanted with CpG protects and boosts heterologous immunity of hACE2 transgenic mice to SARS-CoV-2 infection. Vaccines, No 2023( 11), 01-17. doi:10.3390/vaccines11111732NLM
Russo M, Corrêa MCM, Lins BB, Kersten V, Pernambuco Filho PC de A, Martins TR, Mendoza TRT, Boas LSV, Gomes BM, Dati LMM, Duarte Neto AN, Reigado GR, Frederico ABT, Cunha DR de A de B e, Paula AV de, Silva JIG da, Vasconcelos CFA de, Alcalde FSC, Dantas VANC, Bom APDA, Castilho LR, Martins RAP, Hirata MH, Mirotti L. Intranasal liposomal formulation of spike protein adjuvanted with CpG protects and boosts heterologous immunity of hACE2 transgenic mice to SARS-CoV-2 infection [Internet]. Vaccines. 2023 ; No 2023( 11): 01-17.[citado 2024 set. 01 ] Available from: http://dx.doi.org/10.3390/vaccines11111732Vancouver
Russo M, Corrêa MCM, Lins BB, Kersten V, Pernambuco Filho PC de A, Martins TR, Mendoza TRT, Boas LSV, Gomes BM, Dati LMM, Duarte Neto AN, Reigado GR, Frederico ABT, Cunha DR de A de B e, Paula AV de, Silva JIG da, Vasconcelos CFA de, Alcalde FSC, Dantas VANC, Bom APDA, Castilho LR, Martins RAP, Hirata MH, Mirotti L. Intranasal liposomal formulation of spike protein adjuvanted with CpG protects and boosts heterologous immunity of hACE2 transgenic mice to SARS-CoV-2 infection [Internet]. Vaccines. 2023 ; No 2023( 11): 01-17.[citado 2024 set. 01 ] Available from: http://dx.doi.org/10.3390/vaccines11111732